📊 Key Data
  • February 2, 2026: FDA officially enacted the Quality Management System Regulation (QMSR), retiring the 25-year-old QSIT framework.
  • 35 years: Medicept founder F. David Rothkopf's experience in medical device development, having conducted over 400 audits.
  • 10-minute traceability test: New benchmark for quality teams to trace patient risks from design inputs to postmarket feedback.
🎯 Expert Consensus

Experts agree that the FDA's shift to QMSR represents a fundamental change in medical device inspections, requiring companies to adopt a holistic, risk-based approach to quality management.

about 7 hours ago
The End of QSIT: How the FDA's New QMSR Upends Medtech Inspections

The End of QSIT: How the FDA's New QMSR Upends Medtech Inspections

ASHLAND, Mass. – November 16, 2026 – For anyone who has spent time analyzing corporate risk, there is a distinct moment when a theoretical compliance update turns into a tangible operational crisis. In the medical device sector, that moment arrived on February 2, 2026. On that day, the U.S. Food and Drug Administration officially enacted its Quality Management System Regulation (QMSR), quietly retiring the inspection playbook the industry had relied on for over a quarter of a century.

As a former market analyst, I have always looked for the real stories hiding behind dense regulatory filings. When the FDA shifts its oversight framework, the ripple effects hit a company's bottom line, its operational workflow, and ultimately, its ability to keep products on the market. The transition from the legacy Quality System Inspection Technique (QSIT) to the new QMSR is not just a change in acronyms; it is a fundamental rewiring of how medical device manufacturers must prove their competence.

Next week at MEDevice Silicon Valley in San Jose, Medicept founder F. David Rothkopf is stepping onto the Design Studio Theater stage with a stark warning for the industry. His session, aptly titled "This Is Not Your Father's FDA," aims to shake quality teams out of their decades-old complacency. With 35 years of medical device development experience and more than 400 audits under his belt, Rothkopf is sounding the alarm on a regulatory landscape that has shifted dramatically beneath the industry's feet.

The End of an Era: Retiring the QSIT Playbook

Since the late 1990s, medical device quality teams have built their entire compliance infrastructure around QSIT. That framework was highly compartmentalized, focusing on four distinct subsystems: management control, design control, corrective and preventive actions (CAPA), and production and process controls. Companies knew exactly how to prepare because the test was predictable.

"Most quality teams prepared for an FDA inspection the same way for 25 years, and that preparation no longer matches what happens when the investigator arrives," said F. David Rothkopf, founder of Medicept. "The rules changed in February, but the bigger change is in what investigators ask for and how they follow a problem through the system. I want people to leave this session knowing what to fix before the notice of inspection arrives. No one can promise how an inspection will end, but nobody should be surprised by how it is run."

Under the new QMSR, investigators no longer look at isolated silos. Instead, they start from a company's risk management files and trace those risks relentlessly through the entire quality system. This holistic approach means that a failure in one department is immediately linked to potential patient harm across the product lifecycle.

Unmasking the Data: Internal Audits Are Now Fair Game

Perhaps the most significant operational shock for legacy medtech companies is the sudden loss of confidentiality regarding their internal self-assessments. Under the old rules, documents like management reviews, internal audits, and supplier evaluations were largely shielded from FDA investigators. They were considered safe spaces for companies to identify and hash out their own operational flaws.

That safety net is gone. Under QMSR, these previously protected records are now open books.

Independent regulatory experts and former FDA officials note that this newfound accessibility fundamentally alters the dynamic of an inspection. As one former FDA investigator now in private practice explained, investigators will look directly at internal audit findings to see if a company recognized a systemic failure. If the internal audit flagged an issue but management failed to allocate the resources to fix it, the FDA now has direct evidence of negligence.

This shift places an immense burden on executive leadership. Management reviews can no longer be superficial exercises; they must be robust, accurate, and demonstrate a proactive quality culture. Any deficiencies in these internal processes can now directly trigger Form FDA 483 observations or warning letters.

Ten Minutes to Compliance: The High-Stakes Traceability Test

To help companies navigate this new reality, Medicept has published the "Inspection Readiness Checklist: FDA Inspections After QSIT." The 30-point self-assessment tool is designed to audit quality systems against these modern benchmarks. But one specific metric on that list highlights just how demanding the new environment has become: the ten-minute traceability test.

The checklist challenges quality teams to pick a top patient risk and trace it from initial design inputs all the way to postmarket feedback, having every corresponding record in hand in under ten minutes.

From a data management perspective, this is a monumental task. Legacy paper-based systems or disjointed digital folders simply cannot survive this level of scrutiny. The demand for real-time risk traceability is forcing a massive restructuring of Document Management Systems across the industry.

Medical device companies are increasingly turning to advanced Electronic Quality Management System (eQMS) software vendors, such as Greenlight Guru and MasterControl, to build these digital threads. These platforms are no longer just repositories for static documents; they are dynamic engines designed to link ISO 14971 risk files directly with design controls and complaint handling. During an inspection, the ability to instantly pull a comprehensive, interconnected data trail is now the baseline expectation.

Aligning with Global Standards: The ISO 13485 Equation

Looking at the broader economic picture, the FDA's pivot to QMSR is not an isolated event. It is a strategic alignment with ISO 13485:2016, the international standard for medical device quality management systems.

For multinational corporations, this harmonization is a welcome relief. It reduces the compliance burden of maintaining separate quality systems for the U.S. and European markets. Industry groups like AdvaMed have long championed this alignment, noting that it streamlines global trade and standardizes expectations.

However, for domestic startups and emerging companies that have historically focused solely on FDA clearance, the transition is proving to be a steep climb. The rigorous demands of integrated lifecycle auditing require a level of operational maturity that many younger companies have not yet developed. They are suddenly expected to manage supplier quality and risk traceability with the same sophistication as global enterprise giants.

This is where integrated lifecycle partners like Medicept are finding their critical role. By combining regulatory, quality, clinical, and commercialization expertise—including an in-house clinical research organization—they help companies bridge the gap between legacy practices and modern expectations. Their recent brand refresh, centered around the guiding principle that "patients are waiting," underscores the urgency of this transition. When compliance bottlenecks delay innovation, it is ultimately the healthcare system that suffers.

As industry professionals gather at MEDevice Silicon Valley, the conversations in the hallways will likely echo the warnings from the stage. The era of predictable, compartmentalized FDA inspections has officially closed, and the companies that fail to adapt their data systems and internal cultures will find themselves facing a very different, and far more rigorous, regulatory reality.

Topics & Related

Event:
Policy Change
Sector:
Medical Devices

📝 This article is still being updated

Are you a relevant expert who could contribute your opinion or insights to this article? We'd love to hear from you. We will give you full credit for your contribution.

Contribute Your Expertise →
UAID: 55065